
### HIPAA, ethical, and logistic considerations in cascade testing


Nora B. Henrikson PhD MPH

Kaiser Permanente Washington Health Research Institute, Seattle WA

Implementing Precision and Equitable Public Health in Cascade Testing for Genetic Disorders - A CDC Mini-Symposium and Virtual Panel Discussion

February 10 2022





### Current standard: patient-led disclosure

#### Disclosure to relatives incomplete

- BRCA 73%-75% (Taber 2015, Graves 2014, Fehniger 2013)
- Lynch 67%-98% (Stoffel 2018, Graves 2014)

#### Uptake of cascade testing is low

- 21%-44% HBOC,
- 41%-94% Lynch (Menko 2019)





**Patient** 



At-risk relatives notified








informed decision









### Care team support for patient-led disclosure

PMC7926393 2021; PMID: 34994636 2021



Family genetic counseling

Communication support / training

### Why not notify an at-risk relative?

- Burden
- Unaware of benefit to family
- Strained relationships
- Concern about accuracy, genetics knowledge
- Concern about stressing relatives
- Patient, relative privacy

### Why is patient-mediated disclosure the current standard?


- Care and coverage systems designed for 1:1 care
- Clinician duty, scope of practice
- Liability
- Patient, relative privacy

# Why can't someone other than the patient notify at-risk relatives?

- Direct contact programs combined with patient-led contact reach more relatives than patient-led contact alone
- People conceptualize shared genetic information, family implications

Oh, yeah. I think [health system-led risk notification] would be wonderful ... it would be so much easier instead of me trying to spit out what I think they need to have done or whatever. You folks could do it in a more -- they know what they're talking about and in a more business-like, you know, informational way than I could.

### Alternate paths for disclosure



### Research questions:

Is direct contact of relatives to recommend cascade testing consistent with HIPAA privacy rule?

Is direct contact acceptable to U.S. patients and families?

### Is direct contact of relatives to recommend cascade testing consistent with HIPAA?

- Multidisciplinary working group
- Family vignette, literature review,

Journal of Law and the Biosciences, 1–14 doi:10.1093/jlb/lsaa071 Original Article



### What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?

Nora B. Henrikson<sup>1,\*</sup>, Jennifer K. Wagner<sup>2</sup>, Heather Hampel<sup>3</sup>, Christopher DeVore<sup>4</sup>, Nirupama Shridhar<sup>5</sup>, Janet L. Williams<sup>2</sup>, Katherine E. Donohue<sup>6</sup>, Iftikhar Kullo<sup>7</sup> and Anya E.R. Prince<sup>8</sup>

HIPAA: Health Insurance Portability and Accountability Act of 1996

### Patient-mediated approaches

Considering only HIPAA and not any relevant state laws, may the covered entity (provider):





give their patient <u>information</u> or a '<u>consent to contact</u>' form for family members? Yes.

### Provider-mediated approaches

Considering only HIPAA and not any relevant state laws, may the covered entity (provider):



..directly contact their patient's <u>adult</u> <u>relatives</u> to recommend testing?



directly contact the <u>relative's</u> <u>provider</u> to recommend testing



with patient permission



without patient permission\*



over the patient's objection\*

### Public health approach

Considering only HIPAA and not any relevant state laws, may the covered entity (provider):



directly contact <u>public health authorities</u> to report a patient's genetic risk?

No, unless state public health law makes genetic risk a 'reportable condition'


## Are direct contact programs acceptable to patients and families?


Roberts, M.C.; et al. *Health Aff (Millwood)* **2018**, *37*, 801-808 Menko, F.H et al. *Fam Cancer* **2019**, *18*, 127-135 Andersson, A et al. *Hered Cancer Clin Pract* **2020**, *18*, 18.

#### **Current work**

NHGRI-funded R01HG010144 (Henrikson)


Focus: HBOC, Lynch





Aim 1: Co-design direct contact program with patients and families (complete)

Aim 2: Feasibility trial of KPWA-led direct contact (in process)



### Design round 2 - video



Regardless of the feelings I may have, ultimately after I calm down, I would want to know if I had a greater risk of dying like my sister did at 41. [relative]

SPEAKER 1: Where the doctor knows that someone is at high risk, I mean, shouldn't they contact somebody? ...It's a tradeoff, the privacy versus the health – the lifesaving information. That's what it amounts do, doesn't it?

SPEAKER 2: Maybe. But I think we're forgetting that, like, Molly can also reach out. It's not, like, if the doctor doesn't do it, they're not going to get this information.#

Aspects of direct contact programs were new and raised concerns about whose duty it is to notify relatives and about how privacy would be maintained.

I kind of wonder if, like, if you need consent to do that, like, in your initial intake with Kaiser or, you know, how every so often, is your contact information up to date or all that. And you, like, say can we contact you based on family member information, like, would it be okay if we reached out to you if we find something that might be pertinent to you based on a family member.

Participants thought that direct contact of relatives should be a program, not an individual provider's responsibility. Pre-consenting programs were frequently suggested.

### Requirements for direct contact of relatives

Henrikson 2021 PMID: 34200550 J Pers Med

- U.S.-based health system-led direct contact of relatives
- Has clear potential benefit
- Should take a programmatic approach
- Should include early, pre-disclosure consent of relatives
- Should complement patient-mediated disclosure
- Should allow relatives to control information flow

#### **Current work**

- Direct contact intervention with patient preference for relative contact
  - Letter with phone follow up
  - Relative consultation with genetic counselor
- ❖ Pilot study (n=60 probands), KPWA
- Outcomes: acceptability, feasibility, limited efficacy

